483
Huilai Tianjin ZhangHuilai Tianjin Zhang – FDA 483, Feb 21, 2025
Record Details
An FDA inspection of Hailai Zhang, MD, a clinical investigator in Tianjin, China, revealed significant failures to follow the investigational plan. Observations included delayed reporting of serious adverse events (SAE) and adverse events of special interest (AESI) to the sponsor, as well as incorrect administration of study medication dosages to multiple subjects. These findings indicate critical deviations from protocol requirements.
View Company Profile
ID · a8d9623d-a869-408f-8662-49936f6ba7d6
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.